ViewPoint Therapeutics, a US-based biotechnology spinout focused on eye diseases, yesterday closed a $35m series B round featuring University of Michigan through its Michigan Investment in New Technology Startups (Mints) fund.
The round was led by the Rise Fund, managed by TPG Growth, and also included healthcare company Novo, Mission Bay Capital, Lagunita BioSciences, Biotechnology Value Fund and certain affiliates, and ViewPoint co-founder and chairman Ed Hurwitz.
Founded in 2014, ViewPoint is working on therapies for diseases caused by protein…